Literatur
- 1
Allworth A M.
Tsunami lung: a necrotising pneumonia in survivors of the Asian tsunami.
Med J Austral.
2005;
183
364
- 2
Baddour L M, Yu V L, Klugman K P. et al .
Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal
bacteremia.
Am J Respir Crit Care Med.
2004;
170
440-444
- 3
Balaraman K, Sabesan S, Jambulingam P, Gunasekaran K, Boopathi Doss P S.
Risk of outbreak of vector-borne diseases in the tsunami hit areas of southern India.
Lancet Infect Dis.
2005;
5
128-129
- 4
Barber C G.
CCR5 antagonists for the treatment of HIV.
Curr Opin Investig Drugs.
2004;
5
851-861
- 5
Brauers J, Bagel S, Kresken M.
Aktuelle Resistenzsituation bei bakteriellen Erregern von ambulant erworbenen Atemwegsinfektionen.
Chemother J.
2005;
14
45-53
- 6
Cepeda J A, Whitehouse T, Cooper B. et al .
Isolation of patients in single rooms or cohorts to reduce spread of MRSA in intensive-care
units: prospective two-centre study.
Lancet.
2005;
365
295-304
- 7
Chambers H F.
Community-associated MRSA - Resistance and virulence converge.
New Engl J Med.
2005;
352
1485-1487
- 8
Chastre J, Wolff M, Fagon J Y. et al .
Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia
in adults: a randomized trial.
JAMA.
2003;
290
2588-2598
- 9
Christ-Crain M, Jaccard-Stolz D, Bingisser R. et al .
Effect of procalcitonin guided treatment on antibiotic use and outcome in lower respiratory
tract infections.
Lancet.
2004;
363
600-607
- 10
Cutts F T, Zaman S MA, Enwere G, Jaffar S. et al .
Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive
pneumococcal disease in the Gambia: randomised double-blind, placebo-controlled trial.
Lancet.
2005;
365
1139-1146
- 11
de With K, Schröder H, Meyer E. et al .
Antibiotikaanwendung in Deutschland im europäischen Vergleich.
Dtsch Med Wochenschr.
2004;
129
1987-1992
- 12
Enserink M.
A puzzling outbreak of Marburg Disease.
Science.
2005;
308
31-33
- 13
Esper F, Shapiro E D, Weibel C, Ferguson D, Landry M L, Kahn J S.
Association between a novel human coronavirus and Kawasaki disease.
J Infect Dis.
2005;
191
499-502
- 14
Fouchier R A, Rimmelzwaan G F, Kuiken T, Osterhaus A D.
Newer respiratory virus infections: human metapneumovirus, avian influenza virus,
and human coronaviruses.
Curr Opin Infect Dis.
2005;
18
141-146
- 15
Garcia Vazquez E, Mensa J, Martinez J A. et al .
Lower mortality among patients with community-acquired pneumonia treated with a macrolide
plus a beta-lactam agent versus a beta-lactam agent alone.
Eur J Clin Microbiol Infect Dis.
2005;
24
190-195
- 16
Gonzales E, Kulkarni H, Bolivar H. et al .
The influence of CCL3L1 gene-containing segmental duplications of HIV-1/AIDS susceptibility.
Science.
2005;
307
1434-1440
- 17
Greenspoon S, Carr A.
Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
N Engl J Med.
2005;
352
48-62
- 18
Gupta K, Stamm W E.
Outcomes associated with trimethoprim/sulphamethoxazole (TMP/SMX) therapy in TMP/SMX
resistant community-acquired UTI.
Int J Antimicrob Agents.
2002;
19
554-556
- 19
Herbrecht R, Denning D W, Patterson T F. et al .
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
N Engl J Med.
2002;
347
408-415
- 20
Jahn H, von Graf Luckner A.
Keime, Resistenzen und die DEGAM-Leitlinie.
Z Allg Med.
2003;
79
187-192
- 21
Kahlmeter G.
An international survey of the antimicrobial susceptibility of pathogens from uncomplicated
urinary tract infections: the ECO.SENS Project.
J Antimicrob Chemother.
2003;
51
69-76
- 22
Le T P, Miller L G.
Empirical therapy for uncomplicated urinary tract infections in an era of increasing
antimicrobial resistance: a decision and cost analysis.
Clin Infect Dis.
2001;
33
615-621
- 23
Lietzau S, Sturmer T, Erb A, von Baum H, Marre R, Brenner H.
Prevalence and determinants of nasal colonization with antibiotic-resistant Staphylococcus
aureus among unselected patients attending general practitioners in Germany.
Epidemiol Infect.
2004;
132
655-662
- 24
Mahanty S, Bray M.
Pathogenesis of filoviral haemorrhagic fevers.
Lancet Infectious Diseases.
2004;
4
487-498
- 25
Martinez J A, Horcajada J P, Almela M. et al .
Addition of a macrolide to a ß-lactam-based empirical antibiotic regimen is associated
with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.
Clin Infect Dis.
2003;
36
389-395
- 26
Nguyen H Q, Jumaan A O, Seward J F.
Decline in mortality due to varicella after implementation of varicella vaccination
in the United States.
N Engl J Med.
2005;
352
450-458
- 27
Osterheert J J, Bonten M JM, Hak E, Schneider M ME, Hoepelman I M.
How good is the evidence for the recommended empirical antimicrobial treatment of
patients hospitalized because of community-acquired pneumonia? A systematic review.
J Antimicrob Chemother.
2003;
52
555-563
- 28
Pan A, Carnevale G, Catenazzi P. et al .
Trends in methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections:
effect of the MRSA „search and isolate” strategy in a hospital in Italy with hyperendemic
MRSA.
Infect Control Hosp Epidemiol.
2005;
26
127-133
- 29
Reinert R R, Lütticken R, Bryskier A, Al-Lahham A.
Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric
population in Germany during 2000 - 2001.
Antimicrob Agents Chemother.
2003;
47
489-493
- 30
Reinert R R, Lutticken R, Reinert S, Al-Lahham A, Lemmen S.
Antimicrobial resistance of Streptococcus pneumoniae isolates of outpatients in Germany,
1999 - 2000.
Chemotherapy.
2004;
50
184-189
- 31
Rothberg M B, Wong J B.
All dysuria is local. A cost-effectiveness model for designing site-specific management
algorithms.
J Gen Intern Med.
2004;
19
433-443
- 32
Spellberg B, Powers J H, Brass E P. et al .
Trends in antimicrobial drug development: implications for the future.
Clin Infect Dis.
2004;
38
1279-1286
- 33
Stephens D S, Zughaier S M, Whitney C G. et al .
Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of
the pneumococcal conjugate vaccine: population-based assessment.
Lancet.
2005;
365
855-863
- 34
Stöhr K.
Avian influenza and pandemics - research needs and opportunities.
N Engl J Med.
2005;
352
405-407
- 35
Stürmer T, Erb A, Marre R, Brenner H.
Prevalence and determinants of antibiotic resistance in faecal Escherichia coli among
unselected patients attending general practitioners in Southwest Germany.
Pharmacoepidemiol Drug Safety.
2004;
13
303-308
- 36
Vázquez M, Shapiro E D.
Varicella vaccine and infection with varicella-zoster virus.
N Engl J Med.
2005;
352
439-440
- 37
Weiss K, Low D E, Cortes L. et al .
Clinical characteristics at initial presentation and impact of dual therapy on the
outcome of bacteremic Streptococcus pneumoniae pneumonia in adults.
Can Respir J.
2004;
11
589-593
- 38
Witte W.
Community acquired MRSA weltweit und in Deutschland.
Epidemiol Bull.
2005;
5
33-36
- 39
Zeitlin G A, Maslow M J.
Avian influenza.
Curr Infect Dis Rep.
2005;
7
193-199
- 40
Zetola N, Francis J S, Nuermberger E L, Bishai W R.
Community-acquired methicillin-resistant Staphylococcus aureus: an emerging threat.
Lancet Infect Dis.
2005;
5
275-286
Prof. Dr. Winfried V. Kern
Medizinische Klinik und Poliklinik, Universitätsklinikum
Hugstetter Straße 55
79106 Freiburg
Telefon: 0761/2701819
eMail: kern@if-freiburg.de
